SEC Tracker
Get the app

Enochian Biosciences LNAI

Enochian Biosciences FY 2021: net loss $26.7M

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Enochian Biosciences reported for the year ended Jun 30, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$26.7MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Cash and cash equivalents$20.7MNo year-earlier figure tagged10-K balance sheet, on EDGAR
  3. Cash from operations−$20.6MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Enochian Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Dare Bioscience DARE public float $21M, Jun 30, 2025
  2. Imunon IMNN public float $21M, Jun 30, 2025
  3. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  4. Fibrogen FGEN public float $21M, Jun 30, 2025
  5. Aptose Biosciences APTOF public float $22M, Jun 28, 2025

Data on this page was fetched . The filing on SEC.gov is the record.